Pasotuxizumab (AMG 212) is a 55kDa BiTE molecule that binds to CD3 on T cells and also PSMA on prostate cancer cells, thereby activating the patient’s own T cells to eliminate PSMA-expressing prostate cancer cells. This evidence concerns the gene FOLH1 and prostate carcinoma.